Cara Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

Cara Therapeutics (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors, today announced financial results for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

“We are very pleased with the progress we have made with both I.V. and oral KORSUVA across our ongoing clinical programs in pruritus and with CR845/difelikefalin in pain, including the recent initiation of our first pivotal Phase 3 trial of I.V. KORSUVA in hemodialysis patients with chronic kidney disease-associated pruritus (CKD-aP),” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.  “In 2018, we expect to continue to expand our development programs with KORSUVA for the treatment of other significant unmet pruritus indications, including patients with chronic kidney disease who are not on dialysis, patients with chronic liver disease as well as other dermatological conditions.”

Click here to read the full press release.